References
stroke, n−3 fatty acid, CHD
MYOCARDIAL INFARCTION, CARDIOVASCULAR DISEASE, CVD, STROKE, SECONDARY, EVENTS, CORONARY HEART DISEASE
Results of win ratio analyses for the primary and secondary hierarchical composite outcomes comparing n−3 fatty acid group and its placebo group in all participants of the VITAL study. Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; CI, confidence interval. Results of win ratio analyses for the secondary hierarchical composite outcomes of MI, stroke, and CHD events comparing n−3 fatty acid group and its placebo group in all participants of the VITAL study. Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; CI, confidence interval. Results of win ratio analyses for the primary and secondary hierarchical composite outcomes comparing n−3 fatty acid group and its placebo group in participants with low and high baseline fish consumption in the VITAL study. Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; CI, confidence interval. Reciprocal win ratio < 1 means beneficial effect of n−3 fatty acid supplementation on the composite outcome.Baseline characteristics of the VITAL participants.Abbreviations: VITAL, Vitamin D and Omega-3 Trial; SD, standard deviation; IQR, interquartile range; BMI, body mass index. The number of participants with available BMI data was 12,626 and 12,644 for the n−3 fatty acid and the placebo groups, respectively. The number of participants with available dietary fish intake data was 12,728 and 12,709 for the n−3 fatty acid and the placebo groups, respectively.